Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)

(2011) G K Schwartz et al.   BRITISH JOURNAL OF CANCER

Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer

(2011) K. T. Flaherty et al.   CLINICAL CANCER RESEARCH

Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer

(2011) Gottfried E. Konecny et al.   CLINICAL CANCER RESEARCH

Should there be a standard therapy for mantle cell lymphoma?

(2011) Mitchell R Smith   Future Oncology

A Pilot Study to Evaluate 3'-Deoxy-3'-18F-Fluorothymidine PET for Initial and Early Response Imaging in Mantle Cell Lymphoma

(2011) K. Herrmann et al.   JOURNAL OF NUCLEAR MEDICINE

Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era

(2010) P. Perez-Galan et al.   BLOOD

A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma

(2010) Marta Puyol et al.   CANCER CELL

Responses in Mantle Cell Lymphoma Cells to SNS-032 Depend on the Biological Context of Each Cell Line

(2010) R. Chen et al.   CANCER RESEARCH

Mantle cell lymphoma: The promise of new treatment options

(2010) Andre Goy et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure

(2010) J L Dean et al.   ONCOGENE

Treatment of Growing Teratoma Syndrome

(2009) David J. Vaughn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation

(2009) Tara Barwick et al.   NUCLEAR MEDICINE COMMUNICATIONS

Frontline therapy in mantle cell lymphoma: The role of high-dose therapy and integration of new agents

(2009) Brad S. Kahl   Current Hematologic Malignancy Reports

A Novel Therapeutic Combination Using PD 0332991 and Bortezomib: Study in the 5T33MM Myeloma Model

(2008) E. Menu et al.   CANCER RESEARCH

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

(2008) Annina Herrmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Imaging of Cell Proliferation: Status and Prospects

(2008) J. R. Bading et al.   JOURNAL OF NUCLEAR MEDICINE

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

(2007) E. Hoster et al.   BLOOD